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ABSTRACT
Introduction: Isolated limb perfusion and
infusion (ILP/ILI) are therapies for regional
metastatic melanoma that allow high doses of
anticancer drugs to be delivered directly into
the circulation of an affected limb, thereby
minimizing systemic drug toxicity. This
procedure can lead to high response rates and
is recommended in patients with Stage III
unresectable metastatic melanoma. However,
limited information is available on patterns of
use and costs. This study examined patterns of
ILP/ILI use and associated costs in patients with
melanoma in the United States (US).
Methods: Retrospective, observational study,
using administrative claims data from the
MarketScan databases, was performed in
patients with a diagnosis of melanoma
(ICD-9-CM: 172.xx, V10.82) who underwent
ILP/ILI (CPT-4: 36823) between January 1, 2002
and March 31, 2013. Patient characteristics, use
patterns, length of hospital stay, and costs (per
2014 US $) of ILP/ILI were assessed.
Results: One hundred and thirteen patients
met the study criteria and were included in
the analysis. Mean age was 61.4 years (standard
deviation [SD] 13.8) and 38.9% of patients were
male; the mean baseline Charlson Comorbidity
Index was 0.19; 34.5% of patients were
Medicare beneficiaries. The majority of
patients (87.6%) had melanoma of the lower
limb, 11.5% of the upper limb, and 0.9% of
both limbs; 60.2% had lymph node metastasis
and 56.6% had skin metastasis. Four patients
(3.5%) underwent multiple ILP/ILI. The mean
(±SD) length of hospital stay was 5.6 (±3.5)
days and the mean (±SD) cost was US$36,758
(±27,124) per ILP/ILI procedure.
Conclusions: Isolated limb perfusion and
infusion in patients with melanoma were
associated with long hospital stays and high
costs. These results provide useful source data
for the economic evaluation of treatment
options for regional metastatic melanoma.
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INTRODUCTION
While melanoma accounts for approximately
5% of all skin cancers in the United States (US),
it is responsible for about 90% of all skin cancer
deaths [1–3]. According to the Surveillance,
Epidemiology and End Results (SEER) program,
the incidence of melanoma has been increasing
for the last 30 years. In 2014, there were an
estimated 76,100 new cases and 9710
melanoma-associated deaths in the US [4].
The goals of treatment for melanoma are
cure, local control, or palliation, and are mainly
determined by the stage of disease. For localized
lesions (Stages I and II, American Joint
Committee on Cancer, 7th edition) removal of
the tumor by wide resection is potentially
curative. If there is a loco-regional recurrence
following initial surgery, additional surgical
attempts can be considered [24]. At a certain
point, patients may be considered
unresectable based on the number of failed
prior attempts for surgical cure or the technical
unfeasibility of additional surgery. For patients
with melanoma in-transit (Stage IIIB or IIIC),
the goal of treatment is maintenance of local
disease control and prevention of disease
progression to distant metastases, including
visceral metastases (Stage IV) [5]. For patients
with advanced disease, cure after surgery alone
is rare. The main treatment modality for Stage
IV disease is systemic drug treatment to reduce
tumor burden with the aim of prolonging
survival and decreasing symptoms [6].
Isolated limb perfusion (ILP) and isolated
limb infusion (ILI) are therapeutic modalities
for regional metastatic melanoma with
prevalent in-transit disease, which allow high
doses of anticancer drugs (usually
chemotherapy) to be delivered directly into
the circulation of an affected limb, thus
minimizing systemic drug exposure and
subsequent toxicity. ILP was pioneered by
Creech et al. at Tulane University in the 1950s
[7]. Regional concentrations of
chemotherapeutic agents 15–25 times higher
than those possible with systemic
administration can be achieved with ILP in the
tumor-bearing extremity. The isolation of the
blood vessels of a limb is achieved by clamping
and cannulation of the major artery and vein,
and application of a tourniquet above the
cannulation. ILI, a less elaborate alternative to
ILP, was developed at the Sydney Melanoma
Unit by Thompson et al. in the 1990s [8]. ILI
differs from ILP in that it does not use an
extracorporeal circulation system, making it less
expensive and a shorter procedure requiring
fewer medical resources. To potentiate the effect
of the procedure, infusion or perfusion of the
limb is frequently performed using a
hyperthermic solution of chemotherapeutic
agent (usually melphalan). ILP/ILI is usually
performed in an inpatient setting since both
procedures require anesthesia and use of an
operating room.
ILP/ILI can result in response rates of 30–60%
in melanoma patients [9–11]. However,
randomized clinical trials comparing ILP/ILI
with other treatment modalities are lacking.
ILP, as an adjunct to radical surgery, failed to
demonstrate an improvement in overall
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survival in two randomized clinical trials in
patients with regional metastatic melanoma
[12, 13].
Currently, ILP/ILI is recommended by the
European Society for Medical Oncology (ESMO)
and the US National Comprehensive Cancer
Network (NCCN) Guidelines as a treatment
option for patients with unresectable in-transit
melanoma [14, 15]. ESMO states that
‘‘non-resectable in-transit metastases or
inoperable primary tumors of the limbs without
additional metastases may be treated with ILP
using, e.g., melphalan and/or tumor necrosis
factor-a’’. The NCCN states that ‘‘for patients
with multiple, regional, in-transit metastases,
regional chemotherapy by hyperthermic
perfusion or infusion is an option’’. In the US,
payers such as Blue Cross Blue Shield Health Plans
[16–18], have established a policy that ILP/ILI
should meet medical criteria for coverage when
used as a therapeutic treatment for
unresectable local recurrence of melanoma (i.e.,
satellite lesions or ‘‘in-transit’’ melanoma).
To date, limited information is available in
the literature on patterns of ILP/ILI use and
costs. This study aimed to describe patterns of
ILP/ILI use and estimate associated costs in




This was a retrospective, observational study
using a large administrative claims database
from the Truven Health Analytic MarketScan
databases. The MarketScan database contains
fully adjudicated patient-level medical and
pharmacy claims data for over 40 million
commercially insured and Medicare-insured
patients in 2014. Data elements drawn from
these databases included member demographics
(age, gender, residence region, and enrollment),
dates of service, care setting, diagnostic codes,
procedure codes, and payments.
Study Population
Patients with a diagnosis of melanoma
(ICD-9-CM: 172.xx, V10.82) who underwent
ILP/ILI procedures between January 1, 2002 and
March 31, 2013 in an inpatient setting were
included in this study. The ILP/ILI procedures
were identified by the Current Procedural
Terminology (CPT)-4 code 36823, which
describes the procedures as ‘‘insertion of arterial
and venous cannula(s) for isolated extracorporeal
circulation and regional chemotherapy perfusion
to an extremity, with or without hyperthermia,
with removal of cannula(s) and repair of
arteriotomy and venotomy sites’’. Admission
and discharge dates were identified for each
hospitalization involving an ILP/ILI procedure.
At least one claim of melanoma with an
ICD-9-CM diagnosis code (principal or
secondary) any time between the admission and
discharge dates was required to ensure that the
ILP/ILI procedure was for melanoma treatment.
Outcome Measures
The main outcome measures in this analysis were
patterns of ILP/ILI use, length of hospital stay
(LOS), and hospitalization costs of ILP/ILI. LOS
was calculated based on the number of days
between the admission and discharge dates from
the hospital. Costs were computed as the
combined health plan and patient paid amount,
and were adjusted using the annual medical care
component of the consumer price index to reflect
inflation between 2002 and 2014 [19].
284 Adv Ther (2016) 33:282–289
Results of the analyses are presented
descriptively as mean and median values. All
data were analyzed using SAS programs
organized within SAS Enterprise Guide
version 4.2 (SAS Institute Inc, Cary, NC, USA)
and conducted under UNIX using SAS version
9.2.
Independent Variables
Independent variables included both
demographic and clinical characteristics based
on MarketScan information collected at the
time of hospital admission. Demographic
characteristics included in the analysis were
age, gender, health plan type, Medicare or
commercial beneficiaries, region, and year of
service. Clinical characteristics included
melanoma site, metastatic site, and Charlson
Comorbidity Index score (excluding cancers)
[22, 23].
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Patient Characteristics
A total of 113 patients met the study criteria
and were included in the analysis. Mean patient
age was 61.4 years [standard deviation (SD)
13.8] and 38.9% of patients were male. The
mean baseline Charlson Comorbidity Index
score was 0.19% and 34.5% of patients were
Medicare beneficiaries.
Overall, 87.6% of patients had primary
melanoma of the lower limb, 11.5% of the
upper limb, and 0.9% of both the upper and
lower limbs; 60.2% had lymph node metastasis
and 56.6% had skin metastasis within 1 year
prior to the discharge date of the hospitalization.
A summary of the patient demographic
characteristics is reported in Table 1.
Patterns of ILP/ILI Use
Of the 113 patients identified, the majority
(109/113, [96.5%]) underwent only one
procedure. Four patients (3.5%) underwent
multiple ILP/ILI procedures. Of these four
patients, three underwent ILP/ILI twice, and
one patient underwent three ILP/ILI procedures.
The median time between procedures for these
four patients was 190 days. The use of ILP/ILI
was stable across years, as there was small
amount of procedures (1–23) performed
between 2002 and 2013.
Length of Hospital Stay and Costs
Associated with ILP/ILI
Per ILP/ILI procedure, the mean (±SD) hospital
LOS due to ILP/ILI was 5.6 (±3.5) days. The
median LOS was 5.0 days and the range was
1–22 days. From 2002 to 2013 inclusive, LOS
was generally similar across the years. The mean
LOS for patients with Medicare was 6.3 days,
compared with 5.1 days for patients with
commercial insurance.
The mean cost of ILP/ILI performed in the
inpatient setting was US$36,758 (±27,124) per
procedure. The range of the cost varied
considerably from US$8202 to US$154,008,
with a median cost of US$26,905 (Table 2).
DISCUSSION
This study provides an assessment of use
patterns and costs of ILP and ILI. The mean
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hospital length of stay for ILP/ILI procedures
was 5.6 days and the mean cost was US$36,758
per procedure. To the best of our knowledge,
this is the first study that reports real-world use
patterns and costs of ILP/ILI in a regional
metastatic melanoma population in the US.
Based on the Agency for Healthcare Research
and Quality (AHRQ) Healthcare Cost and
Utilization Project (HCUP), the average
hospital cost (physician cost not included in
the report) for a surgical procedure was
US$20,500 in 2013 [20]. Therefore, the costs of
ILP/ILI procedures are higher than those of an
Table 1 Demographic and clinical characteristics of



















Other plans 14 (12.4)
Medicare beneﬁciaries 39 (34.5)
Regions
Northeast 11 (9.7)





Lower limb 99 (87.6)
Upper limb 13 (11.5)
Both upper and lower limbs 1 (0.9)
Presence of metastasisa






Lymph nodes 68 (60.2)
Skin 64 (56.6)
Charlson Comorbidity Index
(excluding cancer), mean (SD)
0.19 (0.49)













a The site of metastases is not mutually exclusive. It was
identiﬁed 1 year prior to the discharge date of the
hospitalization
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average national surgical procedure. Secondly,
the LOS and costs associated with ILP/ILI
procedures are in line with those associated
with major surgery for metastatic melanoma as
estimated by Zhao et al. [21], where the overall
mean hospital LOS due to surgery was 4.4 days
and the overall mean cost of hospitalization was
US$37,649.
This analysis has limitations. While ILI is
currently more common than ILP, there is no
separate procedure code (CPT) differentiating
ILP from ILI in the claims data. This precludes
an analysis of use patterns and costs separately
for ILP and ILI. Cost per procedure could be
different for ILP and ILI because the ILP
technique involves a more technically
complex and invasive operative procedure,
requiring open surgical cannulation of the
vessels at the root of the extremity. In
comparison to ILP, ILI is a simplified and
minimally invasive operative procedure.
Secondly, the study population was composed
of commercially insured and Medicare-insured
patients, and the patterns and costs of these
procedures may not be representative of all
patients with regional metastatic melanoma,
especially the uninsured or those covered by
Medicaid. Comparison of ILP/ILI with other
alternative therapies for limb melanoma
metastases including electrochemotherapy,
local therapies (interleukin, Rose Bengal,
electrodessication), and systemic therapies was
outside the scope of the current study. This
topic warrants further research.
The current study focused only on
hospitalization cost associated with ILP/ILI,
which can be seen as direct medical costs.
Indirect costs associated with ILP/ILI were not
examined due to lack of indirect cost
information in the database. Considering that
metastatic melanoma affects the working age
population, indirect costs related to the
recovery period at home, concomitant
medication such as antibiotics or painkillers,
and rehabilitation processes could be
considerable and add to the overall costs.
Furthermore, the indirect cost associated with
complication or morbidity due to ILP/ILI could
also be substantial. Thus, the total costs of ILP/
ILI to society can be more expensive than said
in the healthcare claims data.
CONCLUSIONS
The use of ILP and ILI was associated with long
hospital stays and high costs. The results of this
study may provide useful source data for the
economic evaluation of treatment options for
regional metastatic melanoma.
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